The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 02, 2026 for Ravi Agrawal, trustee ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Midcap 150 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Promoter Ravi Agrawal, through the Ravi Agrawal Trust, has disclosed both a release and a fresh creation of pledge on Ajanta Pharma shares under SEBI SAST Regulations. He released pledges on 2,60,000 equity shares — 1,60,000 with Aditya Birla Capital and 1,00,000 with Bajaj Finance — citing 'Excess Pledge' as the reason. Simultaneously, he created a fresh pledge of 2,20,000 shares with The South Indian Bank Ltd for re-financing purposes. On a net basis, pledged shares reduced by 40,000, taking post-event encumbered holding to 60,23,920 shares (4.82% of total share capital) against a promoter holding of 1,62,42,904 shares (13.00%).
This is routine re-financing activity by the promoter — shares have not been sold, and overall promoter pledge burden has only marginally declined. No material impact expected on stock price; reassures investors that the promoter is actively managing debt rather than facing stress.